DCM
ATRC icon

Defilade Capital Management’s AtriCure ATRC Stock Holding History

Defilade Capital Management’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-397,636
Closed -$15.7M – 34
2025
Q4 		$15.7M Buy
+397,636
New +$14.6M 2.13% 21

Other funds holding ATRC

AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Defilade Capital Management's ATRC Position: Q1 2026 in Review

Defilade Capital Management sold out of AtriCure (ATRC) in Q1 2026, closing a stake of 397,636 shares — an estimated $15.7M sold.

Defilade Capital Management first reported a position in ATRC in Q4 2025 and held it in 1 quarter. The position peaked at $15.7M in Q4 2025. 224 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

  • Defilade Capital Management reported no remaining AtriCure position as of Q1 2026 after selling out during the quarter.
  • Defilade Capital Management sold 397,636 AtriCure shares in Q1 2026, an estimated $15.7M.
  • Defilade Capital Management first reported a position in AtriCure in Q4 2025 and held it in 1 quarter.
  • Defilade Capital Management's AtriCure position peaked at $15.7M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on Defilade Capital Management's 13F filing for Q1 2026, filed 14 May 2026.